Osteoporosis drug showdown: alendronate vs teriparatide in new Follow-Up trial
NCT ID NCT06264609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 40 adults with osteoporosis who already completed a year of treatment with either Alendronate or Teriparatide. In this follow-up, participants will switch to the other drug for another year to see which works better for bone loss. The goal is to find a more personalized way to treat age-related bone loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kentucky
Lexington, Kentucky, 40536, United States